|
 |
PAREXEL Early Phase Symposium |
|
Wednesday, 19 October 2016 | 09.30 - 17.00
Dorint an der Messe Basel | Basel Switzerland
View full agenda and topics here.
Basel symposium highlights:
- Key considerations for a strong early development plan
- How and why Biomarkers can provide value to your programs
Justin J. Devine, Chief Medical Officer,
Synexa Life Sciences
- Clinical and Commercial Aspects of PK/PD Modeling
- Learn about PAREXEL Early Phase and Biopharm Unit
- How to find a quality development partner to fund your asset’s development
Claudia Graeve, PhD, Vice President,
Health Advances LLC
- What a potential licensing partner is looking for
Anne-Kathrin Witt, Global BD & Licensing, Head Project Management and Search & Evaluations Cardio-Metabolic,
Novartis Pharma AG
- Coffee, lunch & drinks reception offered
To register, please complete the information below. A confirmation will be sent with details once your RSVP is processed. |
|
|
|
|
|
|
By submitting this form, you consent to receive communications from PAREXEL.
Click here to customize your preferences or opt-out.
©2018 PAREXEL International Corp.
195 West Street Waltham, MA, 02451, USA • Tel: +1 781-487-9900
Privacy Policy | EU-US Privacy Shield Notice | Contact Us
|
|